Prognostic Factors in Resectable Pancreatic Cancer: p53 and Bcl-2

Richard J. Bold, Kenneth R. Hess, A. Scott Pearson, Ana M. Grau, Frank A Sinicrope, Mary Jennings, David J. McConkey, Corazon D. Bucana, Karen R. Cleary, Pamela A. Hallin, Paul J. Chiao, James L. Abbruzzese, Douglas B. Evans

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The p53 tumor suppressor gene and the Bcl-2 proto-oncogene regulate cell cycle progression and apoptosis. We evaluated the expression of these molecular markers with standard pathologic prognostic variables in patients who received multimodality therapy for resectable adenocarcinoma of the pancreas to study the effect of p53 and Bcl-2 on survival duration. Immunohistochemical staining of archival material was performed to determine levels of expression of p53 and Bcl-2 proteins in 70 patients with adenocarcinoma of pancreatic origin. All patients underwent a potentially curative pancreaticoduodenectomy and standardized pathologic analysis of resected specimens. Potential pathologic and molecular prognostic variables were assessed for their effect on survival duration. Nuclear staining for p53 was observed in 33 (47%) of 70 specimens. Immunostaining for Bcl-2 was observed in 23 specimens (33%). A trend toward improved survival duration was seen in patients whose tumors stained positive for either p53 or Bcl-2. Negative staining for both markers predicted short survival (P = 0.01). By univariate and multivariate analyses, no single pathologic factor was associated with survival duration. Immunohistochemical staging using both p53 and Bcl-2 significantly predicted survival duration by univariate and multivariate analysis; patients whose tumors stained positively for p53 and/or overexpressed Bcl-2 had a significantly longer survival than those whose tumors stained negative for both proteins.

Original languageEnglish (US)
Pages (from-to)263-277
Number of pages15
JournalJournal of Gastrointestinal Surgery
Volume3
Issue number3
StatePublished - May 1999

Fingerprint

Pancreatic Neoplasms
Survival
Adenocarcinoma
Multivariate Analysis
Staining and Labeling
Negative Staining
Neoplasms
Pancreaticoduodenectomy
Proto-Oncogenes
Tumor Suppressor Genes
Pancreas
Cell Cycle
Proteins
Apoptosis

Keywords

  • Bcl-2
  • p53
  • Pancreatic cancer
  • Pancreaticoduodenectomy

ASJC Scopus subject areas

  • Surgery

Cite this

Bold, R. J., Hess, K. R., Pearson, A. S., Grau, A. M., Sinicrope, F. A., Jennings, M., ... Evans, D. B. (1999). Prognostic Factors in Resectable Pancreatic Cancer: p53 and Bcl-2. Journal of Gastrointestinal Surgery, 3(3), 263-277.

Prognostic Factors in Resectable Pancreatic Cancer : p53 and Bcl-2. / Bold, Richard J.; Hess, Kenneth R.; Pearson, A. Scott; Grau, Ana M.; Sinicrope, Frank A; Jennings, Mary; McConkey, David J.; Bucana, Corazon D.; Cleary, Karen R.; Hallin, Pamela A.; Chiao, Paul J.; Abbruzzese, James L.; Evans, Douglas B.

In: Journal of Gastrointestinal Surgery, Vol. 3, No. 3, 05.1999, p. 263-277.

Research output: Contribution to journalArticle

Bold, RJ, Hess, KR, Pearson, AS, Grau, AM, Sinicrope, FA, Jennings, M, McConkey, DJ, Bucana, CD, Cleary, KR, Hallin, PA, Chiao, PJ, Abbruzzese, JL & Evans, DB 1999, 'Prognostic Factors in Resectable Pancreatic Cancer: p53 and Bcl-2', Journal of Gastrointestinal Surgery, vol. 3, no. 3, pp. 263-277.
Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M et al. Prognostic Factors in Resectable Pancreatic Cancer: p53 and Bcl-2. Journal of Gastrointestinal Surgery. 1999 May;3(3):263-277.
Bold, Richard J. ; Hess, Kenneth R. ; Pearson, A. Scott ; Grau, Ana M. ; Sinicrope, Frank A ; Jennings, Mary ; McConkey, David J. ; Bucana, Corazon D. ; Cleary, Karen R. ; Hallin, Pamela A. ; Chiao, Paul J. ; Abbruzzese, James L. ; Evans, Douglas B. / Prognostic Factors in Resectable Pancreatic Cancer : p53 and Bcl-2. In: Journal of Gastrointestinal Surgery. 1999 ; Vol. 3, No. 3. pp. 263-277.
@article{a5435ceeb6cf4569906e96f4320fc09d,
title = "Prognostic Factors in Resectable Pancreatic Cancer: p53 and Bcl-2",
abstract = "The p53 tumor suppressor gene and the Bcl-2 proto-oncogene regulate cell cycle progression and apoptosis. We evaluated the expression of these molecular markers with standard pathologic prognostic variables in patients who received multimodality therapy for resectable adenocarcinoma of the pancreas to study the effect of p53 and Bcl-2 on survival duration. Immunohistochemical staining of archival material was performed to determine levels of expression of p53 and Bcl-2 proteins in 70 patients with adenocarcinoma of pancreatic origin. All patients underwent a potentially curative pancreaticoduodenectomy and standardized pathologic analysis of resected specimens. Potential pathologic and molecular prognostic variables were assessed for their effect on survival duration. Nuclear staining for p53 was observed in 33 (47{\%}) of 70 specimens. Immunostaining for Bcl-2 was observed in 23 specimens (33{\%}). A trend toward improved survival duration was seen in patients whose tumors stained positive for either p53 or Bcl-2. Negative staining for both markers predicted short survival (P = 0.01). By univariate and multivariate analyses, no single pathologic factor was associated with survival duration. Immunohistochemical staging using both p53 and Bcl-2 significantly predicted survival duration by univariate and multivariate analysis; patients whose tumors stained positively for p53 and/or overexpressed Bcl-2 had a significantly longer survival than those whose tumors stained negative for both proteins.",
keywords = "Bcl-2, p53, Pancreatic cancer, Pancreaticoduodenectomy",
author = "Bold, {Richard J.} and Hess, {Kenneth R.} and Pearson, {A. Scott} and Grau, {Ana M.} and Sinicrope, {Frank A} and Mary Jennings and McConkey, {David J.} and Bucana, {Corazon D.} and Cleary, {Karen R.} and Hallin, {Pamela A.} and Chiao, {Paul J.} and Abbruzzese, {James L.} and Evans, {Douglas B.}",
year = "1999",
month = "5",
language = "English (US)",
volume = "3",
pages = "263--277",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Prognostic Factors in Resectable Pancreatic Cancer

T2 - p53 and Bcl-2

AU - Bold, Richard J.

AU - Hess, Kenneth R.

AU - Pearson, A. Scott

AU - Grau, Ana M.

AU - Sinicrope, Frank A

AU - Jennings, Mary

AU - McConkey, David J.

AU - Bucana, Corazon D.

AU - Cleary, Karen R.

AU - Hallin, Pamela A.

AU - Chiao, Paul J.

AU - Abbruzzese, James L.

AU - Evans, Douglas B.

PY - 1999/5

Y1 - 1999/5

N2 - The p53 tumor suppressor gene and the Bcl-2 proto-oncogene regulate cell cycle progression and apoptosis. We evaluated the expression of these molecular markers with standard pathologic prognostic variables in patients who received multimodality therapy for resectable adenocarcinoma of the pancreas to study the effect of p53 and Bcl-2 on survival duration. Immunohistochemical staining of archival material was performed to determine levels of expression of p53 and Bcl-2 proteins in 70 patients with adenocarcinoma of pancreatic origin. All patients underwent a potentially curative pancreaticoduodenectomy and standardized pathologic analysis of resected specimens. Potential pathologic and molecular prognostic variables were assessed for their effect on survival duration. Nuclear staining for p53 was observed in 33 (47%) of 70 specimens. Immunostaining for Bcl-2 was observed in 23 specimens (33%). A trend toward improved survival duration was seen in patients whose tumors stained positive for either p53 or Bcl-2. Negative staining for both markers predicted short survival (P = 0.01). By univariate and multivariate analyses, no single pathologic factor was associated with survival duration. Immunohistochemical staging using both p53 and Bcl-2 significantly predicted survival duration by univariate and multivariate analysis; patients whose tumors stained positively for p53 and/or overexpressed Bcl-2 had a significantly longer survival than those whose tumors stained negative for both proteins.

AB - The p53 tumor suppressor gene and the Bcl-2 proto-oncogene regulate cell cycle progression and apoptosis. We evaluated the expression of these molecular markers with standard pathologic prognostic variables in patients who received multimodality therapy for resectable adenocarcinoma of the pancreas to study the effect of p53 and Bcl-2 on survival duration. Immunohistochemical staining of archival material was performed to determine levels of expression of p53 and Bcl-2 proteins in 70 patients with adenocarcinoma of pancreatic origin. All patients underwent a potentially curative pancreaticoduodenectomy and standardized pathologic analysis of resected specimens. Potential pathologic and molecular prognostic variables were assessed for their effect on survival duration. Nuclear staining for p53 was observed in 33 (47%) of 70 specimens. Immunostaining for Bcl-2 was observed in 23 specimens (33%). A trend toward improved survival duration was seen in patients whose tumors stained positive for either p53 or Bcl-2. Negative staining for both markers predicted short survival (P = 0.01). By univariate and multivariate analyses, no single pathologic factor was associated with survival duration. Immunohistochemical staging using both p53 and Bcl-2 significantly predicted survival duration by univariate and multivariate analysis; patients whose tumors stained positively for p53 and/or overexpressed Bcl-2 had a significantly longer survival than those whose tumors stained negative for both proteins.

KW - Bcl-2

KW - p53

KW - Pancreatic cancer

KW - Pancreaticoduodenectomy

UR - http://www.scopus.com/inward/record.url?scp=0033122710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033122710&partnerID=8YFLogxK

M3 - Article

C2 - 10481119

AN - SCOPUS:0033122710

VL - 3

SP - 263

EP - 277

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 3

ER -